APO Research
Talk to an analyst

APO RESEARCH · REPORT

Meningococcal Disease Drugs

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Meningococcal Disease Drugs Industry Growth and Trends Forecast to 2032

19 December 2025105 pages

Choose your research edition.

Industry ResearchMeningococcal Disease Drugs Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Meningococcal Disease Drugs Industry Growth and Trends Forecast to 2032105 pages · $3,450 USDMarket StructureGlobal Meningococcal Disease Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Meningococcal Disease Drugs Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Meningococcal Disease Drugs Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Meningococcal Disease Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Meningococcal Disease Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Meningococcal Disease Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Meningococcal Disease Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Meningococcal Disease Drugs include Yiling Pharmaceutical, SSY Group Limited, Apeloa Pharmaceutical Co.,Ltd., Novartis, Merck Sharp & Dohme, Lukang Pharmaceutical Co.,Ltd., Shandong Jincheng Pharmaceutical Group Co.,ltd., Pfizer and North China Pharmaceutical Company Ltd., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Meningococcal Disease Drugs market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Meningococcal Disease Drugs market size, estimates, and forecasts are presented in terms of sales volume (Tons) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Meningococcal Disease Drugs market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Meningococcal Disease Drugs.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Meningococcal Disease Drugs market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Meningococcal Disease Drugs Market by Company

Yiling Pharmaceutical

SSY Group Limited

Apeloa Pharmaceutical Co.,Ltd.

Novartis

Merck Sharp & Dohme

Lukang Pharmaceutical Co.,Ltd.

Shandong Jincheng Pharmaceutical Group Co.,ltd.

Pfizer

North China Pharmaceutical Company Ltd.

Hebei Hejia Pharmaceutical Technology Group Co., Ltd

Harbin Pharmaceutical Group Co.,Ltd.

GlaxoSmithKline

Baiyunshan Pharmaceutical

Sanofi Pasteur

Meningococcal Disease Drugs Segment by Type

Injectable

Oral

Meningococcal Disease Drugs Segment by Application

Hospitals

Drugstores

Others

Meningococcal Disease Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Meningococcal Disease Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Meningococcal Disease Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Meningococcal Disease Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Meningococcal Disease Drugs manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Meningococcal Disease Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Injectable Table 2. Major Company of Oral Table 3. Global Meningococcal Disease Drugs Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Global Meningococcal Disease Drugs Sales by Type (2021-2026) & (Tons) Table 5. Global Meningococcal Disease Drugs Sales Market Share in Volume by Type (2021-2026) Table 6. Global Meningococcal Disease Drugs Sales by Type (2021-2026) & (US$ Million) Table 7. Global Meningococcal Disease Drugs Sales Market Share in Value by Type (2021-2026) Table 8. Global Meningococcal Disease Drugs Price by Type (2021-2026) & (US$/Ton) Table 9. Global Meningococcal Disease Drugs Sales by Type (2027-2032) & (Tons) Table 10. Global Meningococcal Disease Drugs Sales Market Share in Volume by Type (2027-2032) Table 11. Global Meningococcal Disease Drugs Sales by Type (2027-2032) & (US$ Million) Table 12. Global Meningococcal Disease Drugs Sales Market Share in Value by Type (2027-2032) Table 13. Global Meningococcal Disease Drugs Price by Type (2027-2032) & (US$/Ton) Table 14. North America Meningococcal Disease Drugs Sales by Type (2021-2026) & (Tons) Table 15. North America Meningococcal Disease Drugs Sales by Type (2021-2026) & (US$ Million) Table 16. Europe Meningococcal Disease Drugs Sales by Type (2021-2026) & (Tons) Table 17. Europe Meningococcal Disease Drugs Sales by Type (2021-2026) & (US$ Million) Table 18. Asia-Pacific Meningococcal Disease Drugs Sales by Type (2021-2026) & (Tons) Table 19. Asia-Pacific Meningococcal Disease Drugs Sales by Type (2021-2026) & (US$ Million) Table 20. Latin America Meningococcal Disease Drugs Sales by Type (2021-2026) & (Tons) Table 21. Latin America Meningococcal Disease Drugs Sales by Type (2021-2026) & (US$ Million) Table 22. Middle East and Africa Meningococcal Disease Drugs Sales by Type (2021-2026) & (Tons) Table 23. Middle East and Africa Meningococcal Disease Drugs Sales by Type (2021-2026) & (US$ Million) Table 24. Meningococcal Disease Drugs Industry Trends Table 25. Meningococcal Disease Drugs Industry Drivers Table 26. Meningococcal Disease Drugs Industry Opportunities and Challenges Table 27. Meningococcal Disease Drugs Industry Restraints Table 28. Global Meningococcal Disease Drugs Sales Revenue by Company (US$ Million) & (2021-2026) Table 29. Global Meningococcal Disease Drugs Revenue Market Share by Company (2021-2026) Table 30. Global Meningococcal Disease Drugs Sales by Company (2021-2026) & (Tons) Table 31. Global Meningococcal Disease Drugs Sales Share by Company (2021-2026) Table 32. Global Meningococcal Disease Drugs Market Price by Company (2021-2026) & (US$/Ton) Table 33. Global Meningococcal Disease Drugs Industry Company Ranking, 2024 VS 2025 VS 2026 Table 34. Global Meningococcal Disease Drugs Major Company Production Sites and Headquarters Table 35. Global Meningococcal Disease Drugs Company, Product Type & Application Table 36. Global Meningococcal Disease Drugs Company Establishment Date Table 37. Global Company Market Concentration Ratio (CR5 and HHI) Table 38. Global Meningococcal Disease Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 39. Global Meningococcal Disease Drugs Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 40. Global Meningococcal Disease Drugs Sales by Region (2021-2026) & (Tons) Table 41. Global Meningococcal Disease Drugs Sales Market Share in Volume by Region (2021-2026) Table 42. Global Meningococcal Disease Drugs Sales by Region (2021-2026) & (US$ Million) Table 43. Global Meningococcal Disease Drugs Sales Market Share in Value by Region (2021-2026) Table 44. Global Meningococcal Disease Drugs Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 45. Global Meningococcal Disease Drugs Sales by Region (2027-2032) & (Tons) Table 46. Global Meningococcal Disease Drugs Sales Market Share in Volume by Region (2027-2032) Table 47. Global Meningococcal Disease Drugs Sales by Region (2027-2032) & (US$ Million) Table 48. Global Meningococcal Disease Drugs Sales Market Share in Value by Region (2027-2032) Table 49. Global Meningococcal Disease Drugs Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2027-2032) Table 50. Global Meningococcal Disease Drugs Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 51. Global Meningococcal Disease Drugs Sales by Application (2021-2026) & (Tons) Table 52. Global Meningococcal Disease Drugs Sales Market Share in Volume by Application (2021-2026) Table 53. Global Meningococcal Disease Drugs Sales by Application (2021-2026) & (US$ Million) Table 54. Global Meningococcal Disease Drugs Sales Market Share in Value by Application (2021-2026) Table 55. Global Meningococcal Disease Drugs Price by Application (2021-2026) & (US$/Ton) Table 56. Global Meningococcal Disease Drugs Sales by Application (2027-2032) & (Tons) Table 57. Global Meningococcal Disease Drugs Sales Market Share in Volume by Application (2027-2032) Table 58. Global Meningococcal Disease Drugs Sales by Application (2027-2032) & (US$ Million) Table 59. Global Meningococcal Disease Drugs Sales Market Share in Value by Application (2027-2032) Table 60. Global Meningococcal Disease Drugs Price by Application (2027-2032) & (US$/Ton) Table 61. North America Meningococcal Disease Drugs Sales by Application (2021-2026) & (Tons) Table 62. North America Meningococcal Disease Drugs Sales by Application (2021-2026) & (US$ Million) Table 63. Europe Meningococcal Disease Drugs Sales by Application (2021-2026) & (Tons) Table 64. Europe Meningococcal Disease Drugs Sales by Application (2021-2026) & (US$ Million) Table 65. Asia-Pacific Meningococcal Disease Drugs Sales by Application (2021-2026) & (Tons) Table 66. Asia-Pacific Meningococcal Disease Drugs Sales by Application (2021-2026) & (US$ Million) Table 67. Latin America Meningococcal Disease Drugs Sales by Application (2021-2026) & (Tons) Table 68. Latin America Meningococcal Disease Drugs Sales by Application (2021-2026) & (US$ Million) Table 69. Middle East and Africa Meningococcal Disease Drugs Sales by Application (2021-2026) & (Tons) Table 70. Middle East and Africa Meningococcal Disease Drugs Sales by Application (2021-2026) & (US$ Million) Table 71. Yiling Pharmaceutical Company Information Table 72. Yiling Pharmaceutical Business Overview Table 73. Yiling Pharmaceutical Meningococcal Disease Drugs Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 74. Yiling Pharmaceutical Meningococcal Disease Drugs Product Portfolio Table 75. Yiling Pharmaceutical Recent Development Table 76. SSY Group Limited Company Information Table 77. SSY Group Limited Business Overview Table 78. SSY Group Limited Meningococcal Disease Drugs Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 79. SSY Group Limited Meningococcal Disease Drugs Product Portfolio Table 80. SSY Group Limited Recent Development Table 81. Apeloa Pharmaceutical Co.,Ltd. Company Information Table 82. Apeloa Pharmaceutical Co.,Ltd. Business Overview Table 83. Apeloa Pharmaceutical Co.,Ltd. Meningococcal Disease Drugs Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 84. Apeloa Pharmaceutical Co.,Ltd. Meningococcal Disease Drugs Product Portfolio Table 85. Apeloa Pharmaceutical Co.,Ltd. Recent Development Table 86. Novartis Company Information Table 87. Novartis Business Overview Table 88. Novartis Meningococcal Disease Drugs Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 89. Novartis Meningococcal Disease Drugs Product Portfolio Table 90. Novartis Recent Development Table 91. Merck Sharp & Dohme Company Information Table 92. Merck Sharp & Dohme Business Overview Table 93. Merck Sharp & Dohme Meningococcal Disease Drugs Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 94. Merck Sharp & Dohme Meningococcal Disease Drugs Product Portfolio Table 95. Merck Sharp & Dohme Recent Development Table 96. Lukang Pharmaceutical Co.,Ltd. Company Information Table 97. Lukang Pharmaceutical Co.,Ltd. Business Overview Table 98. Lukang Pharmaceutical Co.,Ltd. Meningococcal Disease Drugs Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 99. Lukang Pharmaceutical Co.,Ltd. Meningococcal Disease Drugs Product Portfolio Table 100. Lukang Pharmaceutical Co.,Ltd. Recent Development Table 101. Shandong Jincheng Pharmaceutical Group Co.,ltd. Company Information Table 102. Shandong Jincheng Pharmaceutical Group Co.,ltd. Business Overview Table 103. Shandong Jincheng Pharmaceutical Group Co.,ltd. Meningococcal Disease Drugs Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 104. Shandong Jincheng Pharmaceutical Group Co.,ltd. Meningococcal Disease Drugs Product Portfolio Table 105. Shandong Jincheng Pharmaceutical Group Co.,ltd. Recent Development Table 106. Pfizer Company Information Table 107. Pfizer Business Overview Table 108. Pfizer Meningococcal Disease Drugs Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 109. Pfizer Meningococcal Disease Drugs Product Portfolio Table 110. Pfizer Recent Development Table 111. North China Pharmaceutical Company Ltd. Company Information Table 112. North China Pharmaceutical Company Ltd. Business Overview Table 113. North China Pharmaceutical Company Ltd. Meningococcal Disease Drugs Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 114. North China Pharmaceutical Company Ltd. Meningococcal Disease Drugs Product Portfolio Table 115. North China Pharmaceutical Company Ltd. Recent Development Table 116. Hebei Hejia Pharmaceutical Technology Group Co., Ltd Company Information Table 117. Hebei Hejia Pharmaceutical Technology Group Co., Ltd Business Overview Table 118. Hebei Hejia Pharmaceutical Technology Group Co., Ltd Meningococcal Disease Drugs Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 119. Hebei Hejia Pharmaceutical Technology Group Co., Ltd Meningococcal Disease Drugs Product Portfolio Table 120. Hebei Hejia Pharmaceutical Technology Group Co., Ltd Recent Development Table 121. Harbin Pharmaceutical Group Co.,Ltd. Company Information Table 122. Harbin Pharmaceutical Group Co.,Ltd. Business Overview Table 123. Harbin Pharmaceutical Group Co.,Ltd. Meningococcal Disease Drugs Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 124. Harbin Pharmaceutical Group Co.,Ltd. Meningococcal Disease Drugs Product Portfolio Table 125. Harbin Pharmaceutical Group Co.,Ltd. Recent Development Table 126. GlaxoSmithKline Company Information Table 127. GlaxoSmithKline Business Overview Table 128. GlaxoSmithKline Meningococcal Disease Drugs Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 129. GlaxoSmithKline Meningococcal Disease Drugs Product Portfolio Table 130. GlaxoSmithKline Recent Development Table 131. Baiyunshan Pharmaceutical Company Information Table 132. Baiyunshan Pharmaceutical Business Overview Table 133. Baiyunshan Pharmaceutical Meningococcal Disease Drugs Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 134. Baiyunshan Pharmaceutical Meningococcal Disease Drugs Product Portfolio Table 135. Baiyunshan Pharmaceutical Recent Development Table 136. Sanofi Pasteur Company Information Table 137. Sanofi Pasteur Business Overview Table 138. Sanofi Pasteur Meningococcal Disease Drugs Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 139. Sanofi Pasteur Meningococcal Disease Drugs Product Portfolio Table 140. Sanofi Pasteur Recent Development Table 141. North America Meningococcal Disease Drugs Market Size Growth Rate (CAGR) by Country (Tons): 2021 VS 2025 VS 2032 Table 142. North America Meningococcal Disease Drugs Sales by Country (2021-2026) & (Tons) Table 143. North America Meningococcal Disease Drugs Sales Market Share by Country (2021-2026) Table 144. North America Meningococcal Disease Drugs Sales Forecast by Country (2027-2032) & (Tons) Table 145. North America Meningococcal Disease Drugs Sales Market Share Forecast by Country (2027-2032) Table 146. North America Meningococcal Disease Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 147. North America Meningococcal Disease Drugs Market Size by Country (2021-2026) & (US$ Million) Table 148. North America Meningococcal Disease Drugs Market Share by Country (2021-2026) Table 149. North America Meningococcal Disease Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 150. North America Meningococcal Disease Drugs Market Share Forecast by Country (2027-2032) Table 151. Europe Meningococcal Disease Drugs Market Size Growth Rate (CAGR) by Country (Tons): 2021 VS 2025 VS 2032 Table 152. Europe Meningococcal Disease Drugs Sales by Country (2021-2026) & (Tons) Table 153. Europe Meningococcal Disease Drugs Sales Market Share by Country (2021-2026) Table 154. Europe Meningococcal Disease Drugs Sales Forecast by Country (2027-2032) & (Tons) Table 155. Europe Meningococcal Disease Drugs Sales Market Share Forecast by Country (2027-2032) Table 156. Europe Meningococcal Disease Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 157. Europe Meningococcal Disease Drugs Market Size by Country (2021-2026) & (US$ Million) Table 158. Europe Meningococcal Disease Drugs Market Share by Country (2021-2026) Table 159. Europe Meningococcal Disease Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 160. Europe Meningococcal Disease Drugs Market Share Forecast by Country (2027-2032) Table 161. Asia-Pacific Meningococcal Disease Drugs Market Size Growth Rate (CAGR) by Country (Tons): 2021 VS 2025 VS 2032 Table 162. Asia-Pacific Meningococcal Disease Drugs Sales by Country (2021-2026) & (Tons) Table 163. Asia-Pacific Meningococcal Disease Drugs Sales Market Share by Country (2021-2026) Table 164. Asia-Pacific Meningococcal Disease Drugs Sales Forecast by Country (2027-2032) & (Tons) Table 165. Asia-Pacific Meningococcal Disease Drugs Sales Market Share Forecast by Country (2027-2032) Table 166. Asia-Pacific Meningococcal Disease Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 167. Asia-Pacific Meningococcal Disease Drugs Market Size by Country (2021-2026) & (US$ Million) Table 168. Asia-Pacific Meningococcal Disease Drugs Market Share by Country (2021-2026) Table 169. Asia-Pacific Meningococcal Disease Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 170. Asia-Pacific Meningococcal Disease Drugs Market Share Forecast by Country (2027-2032) Table 171. Latin America Meningococcal Disease Drugs Market Size Growth Rate (CAGR) by Country (Tons): 2021 VS 2025 VS 2032 Table 172. Latin America Meningococcal Disease Drugs Sales by Country (2021-2026) & (Tons) Table 173. Latin America Meningococcal Disease Drugs Sales Market Share by Country (2021-2026) Table 174. Latin America Meningococcal Disease Drugs Sales Forecast by Country (2027-2032) & (Tons) Table 175. Latin America Meningococcal Disease Drugs Sales Market Share Forecast by Country (2027-2032) Table 176. Latin America Meningococcal Disease Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 177. Latin America Meningococcal Disease Drugs Market Size by Country (2021-2026) & (US$ Million) Table 178. Latin America Meningococcal Disease Drugs Market Share by Country (2021-2026) Table 179. Latin America Meningococcal Disease Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 180. Latin America Meningococcal Disease Drugs Market Share Forecast by Country (2027-2032) Table 181. Middle East and Africa Meningococcal Disease Drugs Market Size Growth Rate (CAGR) by Country (Tons): 2021 VS 2025 VS 2032 Table 182. Middle East and Africa Meningococcal Disease Drugs Sales by Country (2021-2026) & (Tons) Table 183. Middle East and Africa Meningococcal Disease Drugs Sales Market Share by Country (2021-2026) Table 184. Middle East and Africa Meningococcal Disease Drugs Sales Forecast by Country (2027-2032) & (Tons) Table 185. Middle East and Africa Meningococcal Disease Drugs Sales Market Share Forecast by Country (2027-2032) Table 186. Middle East and Africa Meningococcal Disease Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 187. Middle East and Africa Meningococcal Disease Drugs Market Size by Country (2021-2026) & (US$ Million) Table 188. Middle East and Africa Meningococcal Disease Drugs Market Share by Country (2021-2026) Table 189. Middle East and Africa Meningococcal Disease Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 190. Middle East and Africa Meningococcal Disease Drugs Market Share Forecast by Country (2027-2032) Table 191. Key Raw Materials Table 192. Raw Materials Key Suppliers Table 193. Meningococcal Disease Drugs Distributors List Table 194. Meningococcal Disease Drugs Customers List Table 195. Research Programs/Design for This Report Table 196. Authors List of This Report Table 197. Secondary Sources Table 198. Primary Sources List of Figures Figure 1. Meningococcal Disease Drugs Image Figure 2. Global Meningococcal Disease Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Meningococcal Disease Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Meningococcal Disease Drugs Sales (2021-2032) & (Tons) Figure 5. Injectable Image Figure 6. Global Injectable Sales YoY Growth (2021-2032) & (Tons) Figure 7. Oral Image Figure 8. Global Oral Sales YoY Growth (2021-2032) & (Tons) Figure 9. Global Meningococcal Disease Drugs Market Size Overview by Type (2021-2032) & (US$ Million) Figure 10. Global Meningococcal Disease Drugs Market Share by Type 2025 VS 2032 Figure 11. North America Meningococcal Disease Drugs Sales Market Share in Volume by Type in 2025 Figure 12. North America Meningococcal Disease Drugs Sales Market Share in Value by Type in 2025 Figure 13. Europe Meningococcal Disease Drugs Sales Market Share in Volume by Type in 2025 Figure 14. Europe Meningococcal Disease Drugs Sales Market Share in Value by Type in 2025 Figure 15. Asia-Pacific Meningococcal Disease Drugs Sales Market Share in Volume by Type in 2025 Figure 16. Asia-Pacific Meningococcal Disease Drugs Sales Market Share in Value by Type in 2025 Figure 17. Latin America Meningococcal Disease Drugs Sales Market Share in Volume by Type in 2025 Figure 18. Latin America Meningococcal Disease Drugs Sales Market Share in Value by Type in 2025 Figure 19. Middle East and Africa Meningococcal Disease Drugs Sales Market Share in Volume by Type in 2025 Figure 20. Middle East and Africa Meningococcal Disease Drugs Sales Market Share in Value by Type in 2025 Figure 21. Global Top 5 and 10 Meningococcal Disease Drugs Players Market Share by Revenue in 2025 Figure 22. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 23. Hospitals Image Figure 24. Global Hospitals Sales YoY Growth (2021-2032) & (Tons) Figure 25. Drugstores Image Figure 26. Global Drugstores Sales YoY Growth (2021-2032) & (Tons) Figure 27. Others Image Figure 28. Global Others Sales YoY Growth (2021-2032) & (Tons) Figure 29. Global Meningococcal Disease Drugs Market Size Overview by Application (2021-2032) & (US$ Million) Figure 30. Global Meningococcal Disease Drugs Market Share by Application 2025 VS 2032 Figure 31. North America Meningococcal Disease Drugs Sales Market Share in Volume by Application in 2025 Figure 32. North America Meningococcal Disease Drugs Sales Market Share in Value by Application in 2025 Figure 33. Europe Meningococcal Disease Drugs Sales Market Share in Volume by Application in 2025 Figure 34. Europe Meningococcal Disease Drugs Sales Market Share in Value by Application in 2025 Figure 35. Asia-Pacific Meningococcal Disease Drugs Sales Market Share in Volume by Application in 2025 Figure 36. Asia-Pacific Meningococcal Disease Drugs Sales Market Share in Value by Application in 2025 Figure 37. Latin America Meningococcal Disease Drugs Sales Market Share in Volume by Application in 2025 Figure 38. Latin America Meningococcal Disease Drugs Sales Market Share in Value by Application in 2025 Figure 39. Middle East and Africa Meningococcal Disease Drugs Sales Market Share in Volume by Application in 2025 Figure 40. Middle East and Africa Meningococcal Disease Drugs Sales Market Share in Value by Application in 2025 Figure 41. North America Meningococcal Disease Drugs Sales by Country: 2021 VS 2025 VS 2032 (Tons) Figure 42. North America Meningococcal Disease Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 43. North America Meningococcal Disease Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 44. North America Meningococcal Disease Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 45. Europe Meningococcal Disease Drugs Sales by Country: 2021 VS 2025 VS 2032 (Tons) Figure 46. Europe Meningococcal Disease Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 47. Europe Meningococcal Disease Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 48. Europe Meningococcal Disease Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 49. Asia-Pacific Meningococcal Disease Drugs Sales by Country: 2021 VS 2025 VS 2032 (Tons) Figure 50. Asia-Pacific Meningococcal Disease Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. Asia-Pacific Meningococcal Disease Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. Asia-Pacific Meningococcal Disease Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Latin America Meningococcal Disease Drugs Sales by Country: 2021 VS 2025 VS 2032 (Tons) Figure 54. Latin America Meningococcal Disease Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Latin America Meningococcal Disease Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Latin America Meningococcal Disease Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Middle East and Africa Meningococcal Disease Drugs Sales by Country: 2021 VS 2025 VS 2032 (Tons) Figure 58. Middle East and Africa Meningococcal Disease Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Middle East and Africa Meningococcal Disease Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Middle East and Africa Meningococcal Disease Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Meningococcal Disease Drugs Value Chain Figure 62. Key Raw Materials Price Figure 63. Manufacturing Cost Structure Figure 64. Meningococcal Disease Drugs Production Mode & Process Figure 65. Direct Comparison with Distribution Share Figure 66. Distributors Profiles Figure 67. Years Considered Figure 68. Research Process Figure 69. Key Executives Interviewed

Scope & coverage.

Types
  • Injectable
  • Oral
Applications
  • Hospitals
  • Drugstores
  • Others
Companies covered
  • Yiling Pharmaceutical
  • SSY Group Limited
  • Apeloa Pharmaceutical Co.,Ltd.
  • Novartis
  • Merck Sharp & Dohme
  • Lukang Pharmaceutical Co.,Ltd.
  • Shandong Jincheng Pharmaceutical Group Co.,ltd.
  • Pfizer
  • North China Pharmaceutical Company Ltd.
  • Hebei Hejia Pharmaceutical Technology Group Co., Ltd
  • Harbin Pharmaceutical Group Co.,Ltd.
  • GlaxoSmithKline
  • Baiyunshan Pharmaceutical
  • Sanofi Pasteur

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Meningococcal Disease Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Meningococcal Disease Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Meningococcal Disease Drugs Market by Type
  6. 1.3.1 Injectable
  7. 1.3.2 Oral
  8. 1.4 Global Meningococcal Disease Drugs Market Size by Type
  9. 1.4.1 Global Meningococcal Disease Drugs Market Size Overview by Type (2021-2032)
  10. 1.4.2 Global Meningococcal Disease Drugs Historic Market Size Review by Type (2021-2026)
  11. 1.4.3 Global Meningococcal Disease Drugs Forecasted Market Size by Type (2027-2032)
  12. 1.5 Key Regions Market Size by Type
  13. 1.5.1 North America Meningococcal Disease Drugs Sales Breakdown by Type (2021-2026)
  14. 1.5.2 Europe Meningococcal Disease Drugs Sales Breakdown by Type (2021-2026)
  15. 1.5.3 Asia-Pacific Meningococcal Disease Drugs Sales Breakdown by Type (2021-2026)
  16. 1.5.4 South America Meningococcal Disease Drugs Sales Breakdown by Type (2021-2026)
  17. 1.5.5 Middle East and Africa Meningococcal Disease Drugs Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Meningococcal Disease Drugs Industry Trends
  2. 2.2 Meningococcal Disease Drugs Industry Drivers
  3. 2.3 Meningococcal Disease Drugs Industry Opportunities and Challenges
  4. 2.4 Meningococcal Disease Drugs Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Meningococcal Disease Drugs Revenue (2021-2026)
  2. 3.2 Global Top Players by Meningococcal Disease Drugs Sales (2021-2026)
  3. 3.3 Global Top Players by Meningococcal Disease Drugs Price (2021-2026)
  4. 3.4 Global Meningococcal Disease Drugs Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Meningococcal Disease Drugs Major Company Production Sites & Headquarters
  6. 3.6 Global Meningococcal Disease Drugs Company, Product Type & Application
  7. 3.7 Global Meningococcal Disease Drugs Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Meningococcal Disease Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Meningococcal Disease Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Meningococcal Disease Drugs Tier 1, Tier 2, and Tier 3
4 Meningococcal Disease Drugs Regional Status and Outlook
  1. 4.1 Global Meningococcal Disease Drugs Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Meningococcal Disease Drugs Historic Market Size by Region
  3. 4.2.1 Global Meningococcal Disease Drugs Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Meningococcal Disease Drugs Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Meningococcal Disease Drugs Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Meningococcal Disease Drugs Forecasted Market Size by Region
  7. 4.3.1 Global Meningococcal Disease Drugs Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Meningococcal Disease Drugs Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Meningococcal Disease Drugs Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Meningococcal Disease Drugs by Application
  1. 5.1 Meningococcal Disease Drugs Market by Application
  2. 5.1.1 Hospitals
  3. 5.1.2 Drugstores
  4. 5.1.3 Others
  5. 5.2 Global Meningococcal Disease Drugs Market Size by Application
  6. 5.2.1 Global Meningococcal Disease Drugs Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global Meningococcal Disease Drugs Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global Meningococcal Disease Drugs Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America Meningococcal Disease Drugs Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe Meningococcal Disease Drugs Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific Meningococcal Disease Drugs Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America Meningococcal Disease Drugs Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa Meningococcal Disease Drugs Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Yiling Pharmaceutical
  2. 6.1.1 Yiling Pharmaceutical Company Information
  3. 6.1.2 Yiling Pharmaceutical Business Overview
  4. 6.1.3 Yiling Pharmaceutical Meningococcal Disease Drugs Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Yiling Pharmaceutical Meningococcal Disease Drugs Product Portfolio
  6. 6.1.5 Yiling Pharmaceutical Recent Developments
  7. 6.2 SSY Group Limited
  8. 6.2.1 SSY Group Limited Company Information
  9. 6.2.2 SSY Group Limited Business Overview
  10. 6.2.3 SSY Group Limited Meningococcal Disease Drugs Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 SSY Group Limited Meningococcal Disease Drugs Product Portfolio
  12. 6.2.5 SSY Group Limited Recent Developments
  13. 6.3 Apeloa Pharmaceutical Co.,Ltd.
  14. 6.3.1 Apeloa Pharmaceutical Co.,Ltd. Company Information
  15. 6.3.2 Apeloa Pharmaceutical Co.,Ltd. Business Overview
  16. 6.3.3 Apeloa Pharmaceutical Co.,Ltd. Meningococcal Disease Drugs Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Apeloa Pharmaceutical Co.,Ltd. Meningococcal Disease Drugs Product Portfolio
  18. 6.3.5 Apeloa Pharmaceutical Co.,Ltd. Recent Developments
  19. 6.4 Novartis
  20. 6.4.1 Novartis Company Information
  21. 6.4.2 Novartis Business Overview
  22. 6.4.3 Novartis Meningococcal Disease Drugs Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Novartis Meningococcal Disease Drugs Product Portfolio
  24. 6.4.5 Novartis Recent Developments
  25. 6.5 Merck Sharp & Dohme
  26. 6.5.1 Merck Sharp & Dohme Company Information
  27. 6.5.2 Merck Sharp & Dohme Business Overview
  28. 6.5.3 Merck Sharp & Dohme Meningococcal Disease Drugs Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Merck Sharp & Dohme Meningococcal Disease Drugs Product Portfolio
  30. 6.5.5 Merck Sharp & Dohme Recent Developments
  31. 6.6 Lukang Pharmaceutical Co.,Ltd.
  32. 6.6.1 Lukang Pharmaceutical Co.,Ltd. Company Information
  33. 6.6.2 Lukang Pharmaceutical Co.,Ltd. Business Overview
  34. 6.6.3 Lukang Pharmaceutical Co.,Ltd. Meningococcal Disease Drugs Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Lukang Pharmaceutical Co.,Ltd. Meningococcal Disease Drugs Product Portfolio
  36. 6.6.5 Lukang Pharmaceutical Co.,Ltd. Recent Developments
  37. 6.7 Shandong Jincheng Pharmaceutical Group Co.,ltd.
  38. 6.7.1 Shandong Jincheng Pharmaceutical Group Co.,ltd. Company Information
  39. 6.7.2 Shandong Jincheng Pharmaceutical Group Co.,ltd. Business Overview
  40. 6.7.3 Shandong Jincheng Pharmaceutical Group Co.,ltd. Meningococcal Disease Drugs Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Shandong Jincheng Pharmaceutical Group Co.,ltd. Meningococcal Disease Drugs Product Portfolio
  42. 6.7.5 Shandong Jincheng Pharmaceutical Group Co.,ltd. Recent Developments
  43. 6.8 Pfizer
  44. 6.8.1 Pfizer Company Information
  45. 6.8.2 Pfizer Business Overview
  46. 6.8.3 Pfizer Meningococcal Disease Drugs Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Pfizer Meningococcal Disease Drugs Product Portfolio
  48. 6.8.5 Pfizer Recent Developments
  49. 6.9 North China Pharmaceutical Company Ltd.
  50. 6.9.1 North China Pharmaceutical Company Ltd. Company Information
  51. 6.9.2 North China Pharmaceutical Company Ltd. Business Overview
  52. 6.9.3 North China Pharmaceutical Company Ltd. Meningococcal Disease Drugs Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 North China Pharmaceutical Company Ltd. Meningococcal Disease Drugs Product Portfolio
  54. 6.9.5 North China Pharmaceutical Company Ltd. Recent Developments
  55. 6.10 Hebei Hejia Pharmaceutical Technology Group Co., Ltd
  56. 6.10.1 Hebei Hejia Pharmaceutical Technology Group Co., Ltd Company Information
  57. 6.10.2 Hebei Hejia Pharmaceutical Technology Group Co., Ltd Business Overview
  58. 6.10.3 Hebei Hejia Pharmaceutical Technology Group Co., Ltd Meningococcal Disease Drugs Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 Hebei Hejia Pharmaceutical Technology Group Co., Ltd Meningococcal Disease Drugs Product Portfolio
  60. 6.10.5 Hebei Hejia Pharmaceutical Technology Group Co., Ltd Recent Developments
  61. 6.11 Harbin Pharmaceutical Group Co.,Ltd.
  62. 6.11.1 Harbin Pharmaceutical Group Co.,Ltd. Company Information
  63. 6.11.2 Harbin Pharmaceutical Group Co.,Ltd. Business Overview
  64. 6.11.3 Harbin Pharmaceutical Group Co.,Ltd. Meningococcal Disease Drugs Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 Harbin Pharmaceutical Group Co.,Ltd. Meningococcal Disease Drugs Product Portfolio
  66. 6.11.5 Harbin Pharmaceutical Group Co.,Ltd. Recent Developments
  67. 6.12 GlaxoSmithKline
  68. 6.12.1 GlaxoSmithKline Company Information
  69. 6.12.2 GlaxoSmithKline Business Overview
  70. 6.12.3 GlaxoSmithKline Meningococcal Disease Drugs Sales, Revenue and Gross Margin (2021-2026)
  71. 6.12.4 GlaxoSmithKline Meningococcal Disease Drugs Product Portfolio
  72. 6.12.5 GlaxoSmithKline Recent Developments
  73. 6.13 Baiyunshan Pharmaceutical
  74. 6.13.1 Baiyunshan Pharmaceutical Company Information
  75. 6.13.2 Baiyunshan Pharmaceutical Business Overview
  76. 6.13.3 Baiyunshan Pharmaceutical Meningococcal Disease Drugs Sales, Revenue and Gross Margin (2021-2026)
  77. 6.13.4 Baiyunshan Pharmaceutical Meningococcal Disease Drugs Product Portfolio
  78. 6.13.5 Baiyunshan Pharmaceutical Recent Developments
  79. 6.14 Sanofi Pasteur
  80. 6.14.1 Sanofi Pasteur Company Information
  81. 6.14.2 Sanofi Pasteur Business Overview
  82. 6.14.3 Sanofi Pasteur Meningococcal Disease Drugs Sales, Revenue and Gross Margin (2021-2026)
  83. 6.14.4 Sanofi Pasteur Meningococcal Disease Drugs Product Portfolio
  84. 6.14.5 Sanofi Pasteur Recent Developments
7 North America by Country
  1. 7.1 North America Meningococcal Disease Drugs Sales by Country
  2. 7.1.1 North America Meningococcal Disease Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Meningococcal Disease Drugs Sales by Country (2021-2026)
  4. 7.1.3 North America Meningococcal Disease Drugs Sales Forecast by Country (2027-2032)
  5. 7.2 North America Meningococcal Disease Drugs Market Size by Country
  6. 7.2.1 North America Meningococcal Disease Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Meningococcal Disease Drugs Market Size by Country (2021-2026)
  8. 7.2.3 North America Meningococcal Disease Drugs Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Meningococcal Disease Drugs Sales by Country
  2. 8.1.1 Europe Meningococcal Disease Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Meningococcal Disease Drugs Sales by Country (2021-2026)
  4. 8.1.3 Europe Meningococcal Disease Drugs Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Meningococcal Disease Drugs Market Size by Country
  6. 8.2.1 Europe Meningococcal Disease Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Meningococcal Disease Drugs Market Size by Country (2021-2026)
  8. 8.2.3 Europe Meningococcal Disease Drugs Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Meningococcal Disease Drugs Sales by Country
  2. 9.1.1 Asia-Pacific Meningococcal Disease Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Meningococcal Disease Drugs Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Meningococcal Disease Drugs Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Meningococcal Disease Drugs Market Size by Country
  6. 9.2.1 Asia-Pacific Meningococcal Disease Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Meningococcal Disease Drugs Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Meningococcal Disease Drugs Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Meningococcal Disease Drugs Sales by Country
  2. 10.1.1 South America Meningococcal Disease Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Meningococcal Disease Drugs Sales by Country (2021-2026)
  4. 10.1.3 South America Meningococcal Disease Drugs Sales Forecast by Country (2027-2032)
  5. 10.2 South America Meningococcal Disease Drugs Market Size by Country
  6. 10.2.1 South America Meningococcal Disease Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Meningococcal Disease Drugs Market Size by Country (2021-2026)
  8. 10.2.3 South America Meningococcal Disease Drugs Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Meningococcal Disease Drugs Sales by Country
  2. 11.1.1 Middle East and Africa Meningococcal Disease Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Meningococcal Disease Drugs Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Meningococcal Disease Drugs Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Meningococcal Disease Drugs Market Size by Country
  6. 11.2.1 Middle East and Africa Meningococcal Disease Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Meningococcal Disease Drugs Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Meningococcal Disease Drugs Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Meningococcal Disease Drugs Value Chain Analysis
  2. 12.1.1 Meningococcal Disease Drugs Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Meningococcal Disease Drugs Production Mode & Process
  7. 12.2 Meningococcal Disease Drugs Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Meningococcal Disease Drugs Distributors
  10. 12.2.3 Meningococcal Disease Drugs Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst